Amgen Shares Positive Topline Phase 3 Data for Subcutaneous TEPEZZA® in Adults with Moderate-to-Severe Active Thyroid Eye Disease Amgen (NASDAQ: AMGN) has announced positive topline results from a pivotal Phase…
CareQuest Institute Appoints An Nguyen, DDS, MPH, to Serve as Chief Clinical Officer CareQuest Institute for Oral Health has announced the appointment of An Nguyen, DDS, MPH, as its new…
Alcon Introduces Clareon TruPlus Monofocal and Toric IOLs Featuring Advanced Design Innovations at ASCRS 2026 Alcon a global leader in eye care committed to advancing vision health and improving patient…
ZIVO Bioscience Enters Large-Scale Manufacturing Partnership with Cyanotech Corporation to Produce Zivolife™ Algal Biomass Zivo Bioscience, Inc. (OTCQB: ZIVO), a research-driven biotech and agtech innovator specializing in therapeutic, medicinal, and…
Frazier Life Sciences brings on Christian Schade as Senior Advisor to strengthen strategic expertise Frazier Life Sciences (FLS), a well-established investment firm dedicated to advancing innovative biopharmaceutical companies, has announced…
Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies…
Bridge Dental Group Strengthens Its Growing Network by Adding Foothill Family Dental Group and Peak Dental Specialists Bridge Dental Group has announced a significant expansion of its footprint in the…
Glaukos to Showcase Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Corporation (NYSE: GKOS), a leading innovator in ophthalmic pharmaceuticals and medical…
Allevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System Designed for Advanced Spinal Decompression Allevion Medical has announced that it has received clearance from the U.S. Food…
Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi)…
Clarametyx Biosciences Enhances Leadership Team to Advance Clinical Development Initiatives Clarametyx Biosciences, Inc., a clinical-stage biotechnology company focused on developing immune-enabling therapies and vaccines to combat biofilm-driven chronic respiratory diseases,…
Coya Therapeutics Details Upcoming Board Transition, Names Mark H. Pavao as Independent Director Coya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative biologic therapies designed to enhance regulatory…